Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

Gaurav Gupta; Rajiv Dahiya; Yogendra Singh; Anurag Mishra; Aseem Verma; Sunil Kumar Gothwal; Alaa A.a. Aljabali; Harish Dureja; Parteek Prasher; Poonam Negi; Deepak N. Kapoor; Rohit Goyal; Murtaza M. Tambuwala; Dinesh K. Chellappan; Kamal Dua

doi:10.1016/j.cbi.2020.108975

Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

Gaurav Gupta, Rajiv Dahiya, Yogendra Singh, Anurag Mishra, Aseem Verma, Sunil Kumar Gothwal, Alaa A.a. Aljabali, Harish Dureja, Parteek Prasher, Poonam Negi, Deepak N. Kapoor, Rohit Goyal, Murtaza M. Tambuwala, Dinesh K. Chellappan, Kamal Dua

School of Pharm. & Pharmaceut. Sc.

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

77 Downloads (Pure)

Abstract

In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.

Original language	English
Article number	108975
Journal	Chemico-Biological Interactions
Volume	317
Early online date	4 Feb 2020
DOIs	https://doi.org/10.1016/j.cbi.2020.108975
Publication status	Published online - 4 Feb 2020

Keywords

Aldosterone synthase
Angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors
Chronic kidney disease
Hyperkalemia
Renin-angiotensin-aldosterone system

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cbi.2020.108975

Accepted author manuscriptAuthor Accepted Manuscript, 166 KB

Cite this

Gupta, G., Dahiya, R., Singh, Y., Mishra, A., Verma, A., Gothwal, S. K., Aljabali, A. A. A., Dureja, H., Prasher, P., Negi, P., Kapoor, D. N., Goyal, R., Tambuwala, M. M., Chellappan, D. K., & Dua, K. (2020). Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease. Chemico-Biological Interactions, 317, Article 108975. Advance online publication. https://doi.org/10.1016/j.cbi.2020.108975

@article{0b6f0005b0f34b8e9320a158687244eb,

title = "Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease",

abstract = "In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.",

keywords = "Aldosterone synthase, Angiotensin receptor blockers, Angiotensin-converting enzyme inhibitors, Chronic kidney disease, Hyperkalemia, Renin-angiotensin-aldosterone system",

author = "Gaurav Gupta and Rajiv Dahiya and Yogendra Singh and Anurag Mishra and Aseem Verma and Gothwal, {Sunil Kumar} and Aljabali, {Alaa A.a.} and Harish Dureja and Parteek Prasher and Poonam Negi and Kapoor, {Deepak N.} and Rohit Goyal and Tambuwala, {Murtaza M.} and Chellappan, {Dinesh K.} and Kamal Dua",

year = "2020",

month = feb,

day = "4",

doi = "10.1016/j.cbi.2020.108975",

language = "English",

volume = "317",

journal = "Chemico-Biological Interactions",

issn = "0009-2797",

publisher = "Elsevier",

}

Gupta, G, Dahiya, R, Singh, Y, Mishra, A, Verma, A, Gothwal, SK, Aljabali, AAA, Dureja, H, Prasher, P, Negi, P, Kapoor, DN, Goyal, R, Tambuwala, MM, Chellappan, DK & Dua, K 2020, 'Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease', Chemico-Biological Interactions, vol. 317, 108975. https://doi.org/10.1016/j.cbi.2020.108975

TY - JOUR

T1 - Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

AU - Gupta, Gaurav

AU - Dahiya, Rajiv

AU - Singh, Yogendra

AU - Mishra, Anurag

AU - Verma, Aseem

AU - Gothwal, Sunil Kumar

AU - Aljabali, Alaa A.a.

AU - Dureja, Harish

AU - Prasher, Parteek

AU - Negi, Poonam

AU - Kapoor, Deepak N.

AU - Goyal, Rohit

AU - Tambuwala, Murtaza M.

AU - Chellappan, Dinesh K.

AU - Dua, Kamal

PY - 2020/2/4

Y1 - 2020/2/4

N2 - In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.

AB - In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.

KW - Aldosterone synthase

KW - Angiotensin receptor blockers

KW - Angiotensin-converting enzyme inhibitors

KW - Chronic kidney disease

KW - Hyperkalemia

KW - Renin-angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=85079053873&partnerID=8YFLogxK

UR - https://linkinghub.elsevier.com/retrieve/pii/S0009279720300041

U2 - 10.1016/j.cbi.2020.108975

DO - 10.1016/j.cbi.2020.108975

M3 - Article

C2 - 32032593

SN - 0009-2797

VL - 317

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

M1 - 108975

ER -

Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this